Key Takeaways Novartis missed forecasts for quarterly results and guidance, and ended a cancer drug study. The drug maker's sales increased, boosted by its heart medicine, Entresto. Novartis stopped research on an experimental cancer treatment, sabatolimab, after it failed to meet its primary endpoint in a Phase 3 trial. Novartis shares, which hit an all-time high earlier this month, were down more than 3% in mid-afternoon trading. Novartis (NVS) announced fourth-quarter results and guidance Wednesday that ...